| Primary information |
|---|
| sequence ID | Seq_2836 |
| Peptide sequence | GLEEELQFSLGSKINVKVGGNSKGTLKVLR |
| CancerPDF_ID | CancerPDF_ID42, CancerPDF_ID1057, CancerPDF_ID8560, |
| PMID | 16896061,16395409,23667664 |
| Protein Name | Complement C4 precursor,Complement C4 precursor,Complement C3f |
| UniprotKB Entry Name | "CO4A_HUMAN,CO4B_HUMAN",CO4A_HUMAN,CO3_HUMAN |
| Fluid | Serum,Serum,Serum |
| M/Z | 3200.52,3200.52,3199.79 |
| Charge | 1,1,1 |
| Mass (in Da) | 3200.79,NA,3202.72 |
| fdr | NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,FT-ICR MS/MS + nano-HPLC |
| Quantification Technique | NA,NA,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free |
| FDR | NA,less than 1 “5,NA |
| CancerPDF_ID | CancerPDF_ID42, CancerPDF_ID1057, CancerPDF_ID8560, |
| p-Value | 1.00E-05,less than 0.05,NA |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows),MASCOT |
| Length | 30,30,30 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer","Breast cancer, Lung cancer, Rectal cancer" |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,NA |
| Modification | NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])","Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy" |
| Regulation | NA,NA,NA |
| Validation | Independent validation,Independent validation,NA |
| Sensitivity | 95% on independent dataset,97.5% on independent validation dataset,NA |
| Specificity | 95% on independent dataset,NA,NA |
| Accuracy | NA,97.5 % on validation dataset,NA |
| Peptide Atlas | NA |
| IEDB | |